Designing a new drug is a lengthy and expensive process. As the space of potential molecules is very large ( Polishchuk , P. G. ; Madzhidov , T. I. ; Varnek , A. Estimation of the size of drug-like chemical space based on GDB-17 data . J. Comput.-Aided Mol. Des. 2013 , 27 , 675 -679 10.1007/s10822-013-9672-4 ), a common technique during drug discovery is to start from a molecule which already has some of the desired properties. An interdisciplinary team of scientists generates hypothesis about the required changes to the prototype. In this work, we develop a deep-learning unsupervised-approach that automatically generates potential drug molecules given a prototype drug. We show that the molecules generated by the system are valid molecules and significantly different from the prototype drug. Out of the compounds generated by the system, we identified 35 known FDA-approved drugs. As an example, our system generated isoniazid, one of the main drugs for tuberculosis. We suggest several ranking functions for the generated molecules and present results that the top ten generated molecules per prototype drug contained in our retrospective experiments 23 known FDA-approved drugs.

No abstract

No abstract

Designing a new drug is a lengthy and expensive process. As the space of potential molecules is very large (10 23 − 10 60 ), a common technique during drug discovery is to start from a molecule which already has some of the desired properties. An interdisciplinary team of scientists generates hypothesis about the required changes to the prototype. In this work, we develop an algorithmic unsupervised-approach that automatically generates potential drug molecules given a prototype drug. We show that the molecules generated by the system are valid molecules and significantly different from the prototype drug. Out of the compounds generated by the system, we identified 35 FDA-approved drugs. As an example, our system generated Isoniazid -one of the main drugs for Tuberculosis. The system is currently being deployed for use in collaboration with pharmaceutical companies to further analyze the additional generated molecules.